These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 29695239)

  • 1. Bortezomib prevents cytarabine resistance in MCL, which is characterized by down-regulation of dCK and up-regulation of SPIB resulting in high NF-κB activity.
    Freiburghaus C; Emruli VK; Johansson A; Eskelund CW; Grønbæk K; Olsson R; Ek F; Jerkeman M; Ek S
    BMC Cancer; 2018 Apr; 18(1):466. PubMed ID: 29695239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Downregulation of deoxycytidine kinase in cytarabine-resistant mantle cell lymphoma cells confers cross-resistance to nucleoside analogs gemcitabine, fludarabine and cladribine, but not to other classes of anti-lymphoma agents.
    Klanova M; Lorkova L; Vit O; Maswabi B; Molinsky J; Pospisilova J; Vockova P; Mavis C; Lateckova L; Kulvait V; Vejmelkova D; Jaksa R; Hernandez F; Trneny M; Vokurka M; Petrak J; Klener P
    Mol Cancer; 2014 Jun; 13():159. PubMed ID: 24972933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effects of the phosphoinostitide-3'-kinase delta inhibitor, CAL-101, in combination with Bortezomib on mantle lymophma cells and exploration of its related mechanism].
    Qu F; Xia B; Li X; Guo S; Zhang L; Tian C; Yu Y; Zhang Y
    Zhonghua Zhong Liu Za Zhi; 2015 Jun; 37(6):412-7. PubMed ID: 26463142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma.
    Yang DT; Young KH; Kahl BS; Markovina S; Miyamoto S
    Mol Cancer; 2008 May; 7():40. PubMed ID: 18489772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of uptake and resistance to troxacitabine, a novel deoxycytidine nucleoside analogue, in human leukemic and solid tumor cell lines.
    Gourdeau H; Clarke ML; Ouellet F; Mowles D; Selner M; Richard A; Lee N; Mackey JR; Young JD; Jolivet J; Lafrenière RG; Cass CE
    Cancer Res; 2001 Oct; 61(19):7217-24. PubMed ID: 11585758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calcium blockers decrease the bortezomib resistance in mantle cell lymphoma via manipulation of tissue transglutaminase activities.
    Jung HJ; Chen Z; Wang M; Fayad L; Romaguera J; Kwak LW; McCarty N
    Blood; 2012 Mar; 119(11):2568-78. PubMed ID: 22294726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib.
    Sun B; Shah B; Fiskus W; Qi J; Rajapakshe K; Coarfa C; Li L; Devaraj SG; Sharma S; Zhang L; Wang ML; Saenz DT; Krieger S; Bradner JE; Bhalla KN
    Blood; 2015 Sep; 126(13):1565-74. PubMed ID: 26254443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of Lyn is a promising treatment for mantle cell lymphoma with bortezomib resistance.
    Kim A; Seong KM; Kang HJ; Park S; Lee SS
    Oncotarget; 2015 Nov; 6(35):38225-38. PubMed ID: 26517678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deoxycytidine Kinase (DCK) Mutations in Human Acute Myeloid Leukemia Resistant to Cytarabine.
    Wu B; Mao ZJ; Wang Z; Wu P; Huang H; Zhao W; Zhang L; Zhang Z; Yin H; Gale RP; Yin B
    Acta Haematol; 2021; 144(5):534-541. PubMed ID: 33626530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of SAMHD1 expression and mutation status in mantle cell lymphoma: An analysis of the MCL Younger and Elderly trial.
    Roider T; Wang X; Hüttl K; Müller-Tidow C; Klapper W; Rosenwald A; Stewart JP; de Castro DG; Dreger P; Hermine O; Kluin-Nelemans HC; Grabe N; Dreyling M; Pott C; Ott G; Hoster E; Dietrich S
    Int J Cancer; 2021 Jan; 148(1):150-160. PubMed ID: 32638373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug resistance to nelarabine in leukemia cell lines might be caused by reduced expression of deoxycytidine kinase through epigenetic mechanisms.
    Yoshida K; Fujita A; Narazaki H; Asano T; Itoh Y
    Cancer Chemother Pharmacol; 2022 Jan; 89(1):83-91. PubMed ID: 34825941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells.
    Bhalla S; Balasubramanian S; David K; Sirisawad M; Buggy J; Mauro L; Prachand S; Miller R; Gordon LI; Evens AM
    Clin Cancer Res; 2009 May; 15(10):3354-65. PubMed ID: 19417023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clofarabine exerts antileukemic activity against cytarabine-resistant B-cell precursor acute lymphoblastic leukemia with low deoxycytidine kinase expression.
    Huang M; Inukai T; Miyake K; Tanaka Y; Kagami K; Abe M; Goto H; Minegishi M; Iwamoto S; Sugihara E; Watanabe A; Somazu S; Shinohara T; Oshiro H; Akahane K; Goi K; Sugita K
    Cancer Med; 2018 Apr; 7(4):1297-1316. PubMed ID: 29473342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib.
    Dasmahapatra G; Patel H; Dent P; Fisher RI; Friedberg J; Grant S
    Br J Haematol; 2013 Apr; 161(1):43-56. PubMed ID: 23360303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surmounting Cytarabine-resistance in acute myeloblastic leukemia cells and specimens with a synergistic combination of hydroxyurea and azidothymidine.
    Levin M; Stark M; Berman B; Assaraf YG
    Cell Death Dis; 2019 May; 10(6):390. PubMed ID: 31101804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel treatment for mantle cell lymphoma including therapy-resistant tumor by NF-κB and mTOR dual-targeting approach.
    Chaturvedi NK; Rajule RN; Shukla A; Radhakrishnan P; Todd GL; Natarajan A; Vose JM; Joshi SS
    Mol Cancer Ther; 2013 Oct; 12(10):2006-17. PubMed ID: 23963361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bortezomib-resistant nuclear factor κB expression in stem-like cells in mantle cell lymphoma.
    Jung HJ; Chen Z; Fayad L; Wang M; Romaguera J; Kwak LW; McCarty N
    Exp Hematol; 2012 Feb; 40(2):107-18.e2. PubMed ID: 22024108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP/Grp78.
    Roué G; Pérez-Galán P; Mozos A; López-Guerra M; Xargay-Torrent S; Rosich L; Saborit-Villarroya I; Normant E; Campo E; Colomer D
    Blood; 2011 Jan; 117(4):1270-9. PubMed ID: 21106982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro-induced resistance to the deoxycytidine analogues cytarabine (AraC) and 5-aza-2'-deoxycytidine (DAC) in a rat model for acute myeloid leukemia is mediated by mutations in the deoxycytidine kinase (dck) gene.
    Stegmann AP; Honders MW; Hagemeijer A; Hoebee B; Willemze R; Landegent JE
    Ann Hematol; 1995 Jul; 71(1):41-7. PubMed ID: 7543292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ZHX2 mediates proteasome inhibitor resistance via regulating nuclear translocation of NF-κB in multiple myeloma.
    Jiang J; Sun Y; Xu J; Xu T; Xu Z; Liu P
    Cancer Med; 2020 Oct; 9(19):7244-7252. PubMed ID: 32780537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.